How I treat Ph+ acute lymphoblastic leukemia

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is driven by the BCR:ABL1 fusion gene.
• This gene produces a tyrosine kinase, leading to disease and chemotherapy resistance.
• Conventional chemotherapy and HSCT historically offered poor outcomes for Ph+ ALL.

Purpose of the Study:

• To review recent advances in Ph+ ALL treatment.
• To highlight the importance of tyrosine kinase inhibitors (TKIs).
• To discuss the role of immunotherapy and hematopoietic stem cell transplantation (HSCT).

Main Methods:

• Literature review of recent advances in Ph+ ALL treatment.
• Emphasis on tyrosine kinase inhibitors (TKIs) and immunotherapy.
• Analysis of the evolving role of hematopoietic stem cell transplantation (HSCT).

Main Results:

• Tyrosine kinase inhibitors (TKIs) have revolutionized Ph+ ALL treatment, improving survival.
• Immunotherapy, such as blinatumomab, offers new treatment avenues, potentially reducing chemotherapy and HSCT needs.
• Hematopoietic stem cell transplantation (HSCT) remains vital for select high-risk Ph+ ALL cases.

Conclusions:

• TKIs are essential in managing Ph+ ALL.
• Immunotherapy is emerging as a transformative treatment modality.
• Risk-adapted therapy, including judicious use of HSCT, is key for optimal Ph+ ALL management.